JY
CTNM

Jeff Yass’s Contineum Therapeutics CTNM Stock Holding History

Jeff Yass’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Buy
14,300
+3,000
+27% +$39.3K ﹤0.01% 11615
2026
Q1 		$148K Buy
11,300
+1,100
+11% +$14.8K ﹤0.01% 12020
2025
Q4 		$117K Buy
+10,200
New +$116K ﹤0.01% 11365

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's CTNM Position: Q2 2026 in Review

Jeff Yass reduced its Contineum Therapeutics (CTNM) stake by 80% in Q2 2026, selling an estimated $3.88M and leaving 75,559 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #7647.

Jeff Yass first reported a position in CTNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.85M in Q1 2026. 101 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Jeff Yass held 75,559 shares of Contineum Therapeutics worth $1.24M as of Q2 2026.
  • Jeff Yass sold 296,077 Contineum Therapeutics shares in Q2 2026, an estimated $3.88M.
  • Contineum Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7647 holding.
  • Jeff Yass first reported a position in Contineum Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Jeff Yass's Contineum Therapeutics position peaked at $4.85M in Q1 2026.
  • 101 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.